A three-dimensional model of the chemokine receptor CCR5 has been built to fulfill structural peculiarities of its R-helix bundle and to distinguish known CCR5 antagonists from randomly chosen drug-like decoys. In silico screening of a library of 1.6 million commercially available compounds against the CCR5 model by sequential filters (drug-likeness, 2-D pharmacophore, 3-D docking, scaffold clustering) yielded a hit list of 59 compounds, out of which 10 exhibited a detectable binding affinity to the CCR5 receptor. Unexpectedly, most binders tested in a functional assay were shown to be agonists of the CCR5 receptor. A follow-up database query based on similarity to the most potent binders identified three new CCR5 agonists. Despite a moderate affinity of all nonpeptide ligands for the CCR5 receptor, one of the agonists was shown to promote efficient receptor internalization, which is a process therapeutically favorable for protection against HIV-1 infection.
Introduction
G protein-coupled receptors (GPCRs) are among the most investigated therapeutic target families. There are numerous reasons that make GPCRs attractive for the pharmaceutical industry: (i) GPCRs select their endogenous ligands from a uniquely broad chemical space 1 which serves the design of new receptor modulators; 2 (ii) GPCRs have an ubiquitous distribution and regulate a wide array of physiological and pathological processes; 3 (iii) over the last 30 years, many GPCRs have proven to be druggable, 4 and there is a reasonable hope that present and future drug discovery programs will result in the development of drugs acting on other receptors, especially those that are close to well-investigated targets. 5 Notably, the highresolution crystal structure of bovine rhodopsin 6 has paved the way for structure-based design of GPCR ligands. Hence, virtual screening of chemical libraries, which has been successfully used over the last 10 years 7 to design ligands for enzyme targets, may be applied to GPCR homology models based on the rhodopsin template. However, whether GPCR models are reliable starting points is still a matter of debate, 8 mainly because most GPCRs exhibit low sequence similarity (typically less than 30% identity) with bovine rhodopsin. Four recent reports support the optimistic alternative: they describe the use of homology models of rhodopsin-like receptors for structure-based discovery of drug-like sub-micromolar antagonists. [9] [10] [11] [12] In all cases, previous knowledge regarding the interaction between the GPCR and known ligands was necessary to fine-tune the receptor model. Moreover, the choice of a relevant pharmacophore hypothesis was a key factor to downsize a hit list prior to molecular docking. Last, a visual inspection was necessary to ensure that key intermolecular interactions were established with selected hits.
Identifying GPCR agonists by structure-based in silico screening is more challenging, because GPCRs are expected to undergo significant conformational changes upon activation. 13 Retrospective studies that involve the customization of a GPCR active state 3-D models by either discrete rotation of key TM helices 14 or experimentally driven restrained molecular dynamics 15 allowed the recovery of true agonists that were seeded with drug-like random decoys. However, the structure-based discovery of novel GPCR agonists by database screening has not been reported yet. Notably, designing nonpeptide surrogates for endogenous GPCR peptide ligands is highly desirable. 16, 17 In the present paper, we describe the successful virtual screening of a ligand library against a presumed ground state GPCR homology model. By searching for antagonists of the chemokine CCR5 receptor as an attempt to derive anti-HIV agents, 18 we report the unexpected identification of nonpeptide CCR5 agonists.
Results and Discussion
Modeling the Antagonist-Bound Form of the CCR5 Transmembrane (TM) Domain. The 3-D structure of the CCR5 TM domain was built using restraints from the crystal structure of bovine rhodopsin bound to cis-retinal, 6 combined with data from molecular dynamics simulations. 19, 20 The four amino acids of the first extracellular loop (ECL1) were included in the model since the small size of the peptide connecting TMs 2 and 3 greatly limits the arrangement of the two helices. Noteworthy is the TxP motif in TM2; 19 it induces a kink that significantly differs from the bending observed in the bovine rhodopsin template. As a consequence, the distance between TMs 3 and 5 is shortened.
An antagonist binding site was developed by the manual datadriven docking of five well characterized antagonists ( Figure  1 , compounds 1-5) into the receptor cavity and then refined by energy-based optimization of the complexes. The cavity coated with one layer of water molecules bears a size of about 500 Å 3 and a mouth of 70 Å 2 (as computed with Pocket). 21 Eighty percent of the side chains exposed at the cavity surface are hydrophobic or aromatic ( Figure 2A ). All exposed polar residues (Asn/Asp/Gln/Glu/Thr) are located near the pocket mouth, except Asn6.52 and Glu7.39. The negatively charged residue Glu7.39, which is likely to recognize the protonable amine of the receptor antagonists, is found in the vicinity of an aromatic floor in the center of the cavity. This residue actually spans the junction between two hydrophobic subsites ( Figure  2B ). The first subsite is shallow and widely opened. It is delimited by TMs 1, 2, 3, and 7 (Ala1. 31 The CCR5 TM cavity definition, as well as the predicted binding mode for compounds 1-5, was principally assisted by the only mutagenesis study available when we built the model. 22 The investigation of 106 positions allowed a coherent description of a transmembrane binding pocket that was consistent with studies published later. Four recent site-directed mutagenesis studies agree that Glu7.39 in TM7, together with few specific aromatic and hydrophobic residues in TMs 1, 2, 3, 5, and 6, mediate the interaction between the CCR5 receptor and antagonists 1, 23,24 2-3, 23-25 and 4-5 26 (Figure 2A ). These positions are in general agreement with bovine rhodopsin amino acids whose side chains delimit the retinal binding site (Supporting Information Figure S1 ). The only significant mismatch occurred in TM2, where the TxP motif is presumed to stress the helix kink in CCR5. In the refined model, the side chain of Trp2.60, whose mutation in alanine was shown to dramatically decrease the binding of all five antagonists, is directed toward the cavity whereas it would face the lipid bilayer in a homology model obtained by direct threading to the rhodopsin template. It is worth noting that experimental findings suggested that the mutated CCR5 receptors described in the literature remain, to some extent, functional, so that effects observed upon mutation may be due to the loss of key interaction(s) between the ligand and the receptor rather than to the incapability of the ligand to bind to a misfolded or unstable protein.
Customizing a CCR5 Model for Virtual Screening. Preliminary virtual screening experiments demonstrated that the CCR5 model is reliable enough to discriminate known antagonists from randomly chosen drug-like decoys. Docking of the "validation dataset" (containing 1000 molecules, including seven known antagonists 1-7) performed by Gold and Surflex reached satisfactory balance of sensitivity (selection of true positives) and specificity (discard of true negatives). The selection of the 5% best scored molecules produced hit lists that contain about half of the receptor antagonists ( Figure 3 , Supporting Information Table 1 ). In the case of Gold docking, the poses of antagonists found among the top scorers (typically, with fitness values higher than 47) were in general agreement with experimental data, whereas unrealistic poses got poorer scores. From a qualitative point of view, Gold performed better for antagonists that were not expected to be deeply buried in the second subsite. Although better statistics were obtained for Surflex docking, scores assigned to the antagonists did not reflect the docking quality. Typically, the best ranked antagonists exhibited unrealistic poses. The most accurate poses, although not well scored, were obtained for compounds expected to be deeply buried in the second subsite. It was therefore difficult to understand the good performance of the program. We nevertheless decided to use Surflex for prospective screen because the properties and binding modes of molecules selected by this program would most probably differ from that found using Gold.
Virtual Screening. The virtual screening flowchart is summarized in Figure 4 . First, the ligands library setup (or "screening dataset") implied the merging of data available from various suppliers, followed by numerous filtering steps in order to discard non-drug-like, toxic, or reactive compounds as well as frequent hitters. A subset was extracted by picking molecules that meet a simple 2-D pharmacophore (aromatic ring and protonable amine) that is shared by all known CCR5 antagonists. A total of 44 524 compounds were screened in parallel by high throughput docking using both Gold and Surflex. The postprocessing procedure was set up in light of the results obtained for the preliminary retrospective screening of the "validation dataset". For the Gold prospective screen, the fitness threshold was thus set to 47. This cutoff yielded the selection of about 5% of the entire database. For the Surflex prospective screen, we set the pK i threshold to 8 (together with a bump score limit of -40) so that about 5% of the docked database is selected too. In this way we could apply the same postprocessing rules to both docking runs. Less than 100 compounds were common to Surflex and Gold hitlists (and among them only 5 shared compatible poses), thereby advocating separate processing of Surflex and Gold runs rather than using consensus methods. Potential hits of the two lists were independently classified by graph-based maximum common substructures (MCS). A postprocessing procedure retained only classes (MCS) enriched enough in well-scored molecules. Compound sampling followed by visual inspection of predicted binding mode returned a final list of 77 molecules.
Validated hits Are Mostly Competitive Agonists of the Receptor. From the 77 virtual hits, 59 compounds could be purchased and tested experimentally for their ability to bind to the CCR5 receptor expressed in CHO_K1 cells and to modify the receptor functional response in an aequorin luminescence assay. The binding properties of the compounds to the CCR5 receptor were measured in a competition binding assay, using radiolabeled MIP1-(CCL4) as a tracer, and the compounds at two concentrations (10 and 100 µM). The functional properties of the binders were then tested (at 1, 10, and 100 µM) by measuring intracellular calcium release, using a reporter assay based on light emission by the apoaequorin-coelenterazine complex in cell lines expressing the CCR5 receptor together with apoaequorin.
Out of the 59 compounds tested, 10 exhibited detectable binding activity to the CCR5 receptor in the primary screening and 6 were picked based on their functional response. Five of the hits were common to both assays, and the 10 hits were confirmed in subsequent dose response curves. Unexpectedly, most binders were characterized as agonists in the aequorinbased functional assay. Although many of the compounds displayed weak affinities and/or potencies, four molecules, namely 8-11, exhibited affinities in the high micromolar range ( Figure 5 , Table 1 , and Supporting Information Figure S2 ), and compounds 8, 10, and 11 were able to stimulate CCR5-mediated calcium release at similar concentrations.
The three most potent ligands 8, 9, and 11 share common pharmacophoric features: (i) a central nitrogen-rich scaffold (triazole, benzotetrahydropiperazinone, and benzimidazole), (ii) a protonable nitrogen atom at the extremity of an aliphatic side chain, (iii) one aromatic ring connected to the scaffold by linker groups of variable length. However, Tanimoto similarity coefficients estimated from FCFP_4 fingerpints 27 indicate that the investigated compounds (1-11) are rather diverse. Moreover, CCR5 antagonists (compounds 1-7, 9) and agonists (compounds 8, 10, 11) do not show higher mean pairwise Tanimoto similarity within the set than between sets.
The predicted binding mode of compounds 8, 9, and 11 is described in Figure 6 . Like antagonists, agonists are all anchored to the cavity by a salt bridge between the protonated amine of the ligand and Glu7.39 carboxylate. Aromatic rings of compounds 9 and 11 are embedded in the subsite 2 (TMs 3, 5, and 6). By contrast, aromatic interactions observed for compound 8 involve Trp and Tyr residues of subsite 1 (TMs 1, 2, and 3) . In addition, the amide oxygen atom of 8 is H-bonded to the Trp93 side chain (EL1). It is however worth noting that compound 8 comes from the Gold screen whereas compounds 9 and 11 are hits from the Surflex screen; therefore, the observed binding modes may be biased by docking program hallmarks. Site-directed mutagenesis of residues predicted to interact with the described agonists is however mandatory to validate the hypothesis of overlapping binding sites.
Ground State GPCR Homology Models Are Suitable for Retrieving Full Agonists. CCR5 endogenous ligands are large peptides, namely chemokines such as macrophage inflammatory protein-1R (MIP-1R, CCL3), MIP-1 (CCL4), RANTES (CCL5), and MCP-2 (CCL7). The chemokine core domain contacts the receptor extracellular domains, 28 while the N-terminus of several chemokines has been proposed to mediate receptor activation by interacting with the transmembrane helix bundle. 29 The CCR5 receptor TM cavity is known to accommodate small molecules that inhibit the receptor response to chemokines by an allosteric mechanism. 30, 31 The present work proves the utility of the modeled TM domain structure for the discovery of nonpeptide modulators of the CCR5 receptor. Surprisingly, the putative ground state CCR5 receptor model resulted in the identification of agonists. Our finding hence hints that a single CCR5 structure might bind small molecules that can either favor the active or inactive state of the receptor. This assumption is supported by the recent crystal structure of the photoactivated deprotonated intermediate of bovine rhodopsin, which clearly demonstrated that the ground state and the described metaII activated state of the receptor are structurally similar 32 and that the acknowledged large scale structural rearrangement of the receptor transmembrane domain upon activation is overestimated.
Agonist-Induced CCR5 Receptor Internalization. Several reports have suggested that internalizing the CCR5 receptor may constitute a very efficient strategy to block HIV infection: (i) the capability to favor internalization of CCR5 has been demonstrated to be strongly related to the antiviral properties of RANTES derivatives; 33 (ii) a lower susceptibility to HIV infection has been reported for individuals presenting multiple copies of the gene encoding the CCR5 agonist MIP-1R, 34 (iii) small chemical agonists promoting internalization of the receptor might prevent the selection of HIV mutants that would be able to interact with CCR5 bound to the allosteric inhibitors presently tested in clinical trials.
The potency of compounds 8, 9, and 11 to induce the CCR5 receptor internalization was investigated by monitoring the fluorescence of the receptor fused to the Enhanced Green Fluorescent Protein variant (EGFP). 35 All three compounds promote CCR5 receptor internalization, yet poor efficiency was observed for compounds 9 and 11 (5 ( 2% and 15 ( 2% of receptor internalized after 15 min, respectively). On the other hand, the level of internalized receptors in the presence of compound 8 at a concentration of 20 µM reached 22% ( 2% (Figure 7) . By the way of comparison, the reference value measured in presence of chemokine RANTES (CCL5) at 200 nM was 37% ( 3%. Molecule 8 thus appears to be a good hit for further development of CCR5-internalizing nonpeptide agents ( Figure 7) .
Follow-Up Similarity Search Identifies Other CCR5 Receptor Agonists. In an attempt to find more potent CCR5 receptor agonists, we have undertaken a ligand-based virtual screening to find novel agonists similar to three previously identified hits (compounds 8, 10, and 11). Different screening strategies using various templates and 2-D fingerprints (Table  2) were followed to optimize the chances to find novel hits. 36 Out of the starting 1 186 452 library compounds ("updated screening dataset"), 62 761 shared physicochemical properties as well as key pharmacophoric features exhibited by compounds 8, 10, and 11. Four independent ligand-based screens of this dataset were performed using various 2-D fingerprint representations (circular FCFP-4 fingerprints, MPMFP, Unity 2D, see Table 2 ). One hundred compounds were manually selected from the four hit lists. Seventeen close analogs of agonist 8 were chosen in order to derive SAR rules, and the 83 other compounds were picked to optimize chemical diversity according to ClassPharmer maximum common substructures. Experimental testing for CCR5 functional response revealed 7 additional true positives that were characterized by an EC 50 below 100 µM. The three most potent compounds 12-14 were tested in a CCR5 binding assay and shown to compete for MIP-1 binding (Table 1 , Figure S2 Supporting Information). Compounds 13 and 14 display enhanced affinity for CCR5 as compared to compound 8. The lack of activity of the 17 close analogs of compound 8 suggests that both the distance between triazole and piperidine rings and the nature of substituents in the terminal anilide moiety are important for the binding to the CCR5 receptor.
Nonpeptide Agonists of Chemokine Receptors. Very few nonpeptide agonists are known for the members of the chemokine receptor family. Detailed characterization of a nonpeptide low molecular-weight agonist is available for the CCR8 receptor subtype. 37 Nonpeptidic modulators of the chemokine receptor are also described for the CCR3 receptor subtype. 38 Interestingly, structure-activity relationships developed for the investigated series indicated that minor chemical modifications may switch compound activity from antagonist to agonist. Another striking example is reported for the CCR3 receptor by De Lucca and coworkers, 39 who observed that quaternary piperidium salts were agonists while corresponding piperidine derivatives were antagonists of the receptor.
The present work describes several novel CCR5 receptor nonpeptide antagonists and agonists ( Figure 5 ), discovered by ligand-and structure-based virtual screening. All compounds share a protonable tertiary amine and several aromatic rings that are expected to interact with key residues in the TM domain of the receptor. Similar features were observed in the CCR5 agonist YM-370749 40 that was very recently discovered by Saita and co-workers 40 by high-throughput screening. Like compound 8, YM-370749 is able to induce the intracellular accumulation of the CCR5 receptor. Interestingly, it did not stimulate undesirable chemotaxis. Provided that compound 8 does not trigger undesirable proinflammatory activities, it is an attractive candidate for the design of a new class of anti-HIV agent, because its computed molecular properties are compatible with oral bioavailability.
Conclusions
A 3-D model of the CCR5 receptor was derived from the inactive dark state of bovine rhodopsin and then customized to discriminate true CCR5 antagonists from drug-like decoys and finally utilized for the in silico screening of commercially available compound libraries. Out of 59 molecules selected by a series of logical filters of increasing complexity, 10 compounds were found to display micromolar affinities to the CCR5 receptor. Unexpectedly, six hits were found to be agonists of the target receptor, and no obvious chemical features could discriminate between agonist and antagonist compounds. Our findings show that the current CCR5 receptor model is suitable for retrieving both agonist and antagonist compounds, suggesting that the TM structure of the activated and inactivated states of the receptor are similar, as recently demonstrated for bovine rhodopsin. 32 A follow-up ligand-based virtual screening identified three new CCR5 agonists exhibiting 2-D fingerprints which were similar to the first-generation hits. One of the nonpeptide CCR5 agonists (compound 8) was shown to promote efficient receptor internalization, which is a process therapeutically favorable for protection against HIV-1 infection.
Computational Methods
Molecular Modeling. The 3-D coordinates of a previously published 3-D model of the CCR5 R-helix bundle 19, 20 were kindly provided by C. Govaerts and L. Pardo. After addition of the first intracellular loop that constrains TMs 2 and 3 inner relationships, the starting model was first minimized in AM-BER6.0 41 in vacuum using the parm98 parameter set. Five cycles of 500 steps of steepest descent followed by 500 steps of conjugated gradient were applied as followed; first, all R carbons of the TM domain were constrained using a harmonic constant of 50 kcal/mol/Å. Next, the constant value was gradually reduced to zero, and finally, the last minimization round ended after 10 000 steps, resulting in rms gradient of the potential energy in the 0.05-0.01 kcal/ mol/Å range.
Further refinement aimed at the fit of nonpeptide ligands into the TM cavity. An N-terminal binding pocket enclosing 33 residues (residues in red, Figure 2A ) was defined by similarity with the 11-cis-retinal binding site found in the bovine rhodopsin crystal structure. It was optimized in order to accommodate a set of five known CCR5 antagonists: TAK-779, SCH-351125, SCH-350634, and representative structure of 1-amino-2-phenyl-4-(piperidin-1-yl)butane and 1,3,4-trisubstituted pyrrolidines from a Merck series (Figure 1: compounds 1-5) . The ligand starting conformation consisted of the 3-D coordinates generated by Concord 42 from IsisDraw 43 2-D sketches. Their most likely ionization state at physiological pH was set manually. All antagonists were manually docked according to existing sitedirected mutagenesis 22 and detailed structure-activity relationships. [44] [45] [46] [47] [48] [49] [50] [51] Both rotatable bonds of ligand and torsional angles of residues of the putative binding pocket were adjusted to avoid intermolecular steric clashes. The five reference antagonists were parametrized for Amber6.0 according to a previously described procedure. 52 Energy minimization of each complex was realized as describe above. A distance restraint ensured the interaction between the positively charged nitrogen atom of the ligand and any of the carboxylate oxygen atoms of Glu7.39. At last, the coordinates of the five receptor-bound minimized ligands were merged into the TAK779-bound minimized CCR5 structure, and the resulting supramolecule was optimized by energy minimization (see above parameters) using the AMBER belly approach that allowed the ligand atoms to remain at fixed positions during protein refinement.
Structure-Based Virtual Screening. 1. Databases Setting. Starting from 1 620 316 commercially available compounds (sd format) collected from eight suppliers (Asinex, Bionet, Chembridge, Chemdiv, InterBioScreen, Maybridge, Specs, TriposLeadquest), 431 029 unique drug-like compounds were selected by properties and functional groups 53 using the Filter1.0 program 54 and then ionized at physiological pH using Filter again and finally converted into 3-D coordinates (mol2 format) by Concord. 42 A subsequent filtering step by 2-D pharmacophore search afforded 44 524 compounds sharing an aromatic ring and a protonable nitrogen atom ("screening dataset").
Seven known CCR5 antagonists ( Figure 1 , compounds 1-7) together with 993 molecules randomly chosen from the screening dataset were incorporated in a separate library to create a "validation dataset" of 1000 molecules.
2. High Throughput Docking. All molecules of the databases were docked into the final CCR5 model using Gold2.0 55 and Surflex1.1. 56 Library screening settings of Gold were used to generate a maximum of 10 poses for each molecule. Poses were evaluated using Goldscore. The binding cavity was defined from the center of mass of 33 residues previously selected to define the antagonist-binding pocket. Early termination of the genetic algorithm was allowed whether the top three ranked poses were within 1.5 Å rms deviations.
Surflex docking was performed using the "whole molecule" approach (-whole), a maximum of 100 simultaneously considered posed fragment in each stage of the incremental construction process (-maxconf 100) and default settings for all other parameters. The protomol based on protein residues that form the CCR5 binding pocket as defined above contains 451 points.
3. Postprocessing and Hit Triage. Two independent hitlists were obtained by selecting the top ranked molecules proposed by Gold and Surflex (Figure 4) . Defining a Goldscore threshold of 47 yielded the selection of a first list of 2410 molecules from Gold poses. A second set of 2724 molecules was retained from Figure 6 . View of complexes between the CCR5 receptor cavity and agonists 8 (magenta) and 11 (cyan), and antagonists 1 (orange) and 9 (green). Ligands and side chains of protein residues that are less than 4 Å apart are shown inside the transparent Connolly surface of the protein channel using ball and stick and stick representation, respectively. Oxygen atoms are displayed in red, nitrogen atoms in dark blue, and sulfur atoms in yellow. For the sake of clarity, protein carbon atoms are colored in white and ligand carbon atoms followed the above-mentioned color code.
Surflex poses by combining a Surflex score threshold value of 8 and a penetration threshold value of -40. The two hitlists were separately clustered according to common graph-based scaffolds using the ClassPharmer 3.5 program. 57 The clustering procedure was performed using the medium setting for homogeneity and redundancy parameters, and allowed fuzzy ring closure. All molecules discarded by the docking score-based selection were imported into each classification. Classes were then prioritized according to distribution of docking scores and the proportion of imported compounds in each class. Compound sampling retrieved the best scored molecule for each selected class in order to produce a hit list. Last, relevance of the potential hits was assessed using a visual check of the receptor-hit geometry. More especially, the visual analysis relied on (1) surface complementarity between the ligand and the protein, (2) the percentage of the ligand surface buried in the complex, (3) the amount and the properties of ligand surface that is exposed to solvent, (4) the number of occluded polar atoms of both ligand and protein in the complex, (5) the establishment of a salt bridge to the carboxylate of Glu7.39, and (6) the strain energy of the bound ligand. Altogether, two lists of 38 and 43 compounds, respectively, were selected from Gold and Surflex docking runs and merged to afford a final list of 77 compounds to purchase.
Ligand-Based Virtual Screening for Hit Optimization. A total of 1 186 452 unique drug-like and commercially available compounds were filtered as described above. The stepwise ligand-based screen of the database ("updated screening dataset") was performed as follows: first, a substructure search yielded 89 121 compounds that contain a positively charged nitrogen atom together with an aromatic bond and ring-membered sp 2 nitrogen atom. Subsequent filtering according to physicochemical properties of compounds 8, 10, and 11 (molecular weight ranging from 300 to 480, less than 10 rotatable bonds and more than two aromatic rings) selected 62 761 compounds. Last, similarity searches to compounds 8, 10, and 11 was carried out using a Tanimoto coefficient (Tc) as similarity metric and three different fingerprints, namely FCFP_4 circular fingerprints as implemented in PipelinePilot 5.1, 27 MPMFP 58 as implemented in MOE 2006.06, and UNITY 2D fingerprint as implemented in Sybyl7.1. 42 Virtual hits were merged and clustered using ClassPharmer 3.5. 57 A total of 100 compounds were finally picked based on human expertise out of which 83 could be purchased.
Experimental Procedures
Cell Lines. A construct encoding wild-type CCR5 in the pEFIN3 bicistronic vector was transfected in a CHO-K1 cell line expressing an apoaequorin variant targeted to mitochondria, and a stable cell line was established as described. 59 CHO-K1 cells were cultured in HAM's F12 medium supplemented with 10% fetal calf serum (Life Technologies), 100 units/mL penicillin, and 100 µg/mL streptomycin (Life Technologies).
Binding Assays. CHO-K1 cells expressing wild-type or mutant CCR5 were collected from plates with Ca 2+ -and Mg 2+ -free PBS supplemented with 5 mM EDTA, gently pelleted by centrifuging for 2 min at 1000g, and resuspended in binding buffer ( 42 90 min at 27°C, and then bound tracer was separated by filtration through GF/B filters presoaked in 0.1% bovine serum albumin (Sigma). Filters were counted in a -scintillation counter. Assays were performed in triplicate.
Aequorine Assay. Functional response to ligands was analyzed by measuring the luminescence of aequorin as described. 59 Cells were collected from plates with Ca 2+ -and Mg 2+ -free DMEM supplemented with 5 mM EDTA. They were then pelleted for 2 min at 1000g, resuspended in DMEM at a density of 5 × 10 6 cells/ mL, and incubated for 2 h in the dark in the presence of 5 µM coelenterazine H (Molecular Probes). Cells were diluted 5 fold before use. Agonists in a volume of 50 µL of DMEM were added to 50 µL of cell suspension (50 000 cells) and luminescence was measured for 30 s in a Berthold Luminometer. Assays were performed in duplicate.
Internalization of EGFP-CCR5 Receptors Measured Using Anti-GFP Antibodies. HEK 2193 cells expressing EGFP-CCR5 receptor were suspended at a concentration of 10 6 cells/mL in 24 mL of HEPES-BSA buffer. The cell suspension was distributed into 4 × 50 mL tubes equipped with magnetic stirring and incubated at 37°C. At time-point 0, control or test compounds were added to each sample. The final concentration of RANTES (CCL5) was 200 nM. The final concentration of test compounds was chosen according to measured IC 50 determined (20 µM for compound 8 and 100 µM for compounds 9 and 11). At time points 0, 5, 15, 30, and 45 min, 1 mL of each cell suspension was collected, pelleted by centrifuging for 3 min at 2000g at 4°C and resuspended in 1 mL of ice-cold PBS-1% BSA. Immunolabeling of EGFP-CCR5 receptors expressed at the surface was performed by incubation for 30 min on ice with a monoclonal mouse anti-GFP (Roche Molecular Biochemicals; 1/100 dilution). Cell were then washed three times with 1 mL of ice-cold PBS-1% BSA, and secondary labeling was done using R-phycoerythrin-conjugated AffiniPure F(ab)2 fragment goat antimouse IgG (Immunotech, Marseille; 1/100). Samples were washed twice with 1 mL of PBS, fixed for 5 min in ice-cold PBS-4% paraformaldehyde, resuspended in 1 mL of ice-cold PBS, and stored overnight. Phycoerythrin staining was quantified by flow cytometric analysis (FACScalibur, BectonDickinson) using 5000 cells per sample. The mean intensity of phycoerythrin fluorescence was calculated using CELLQuest (Becton-Dickinson) software, after subtraction of nonspecific staining by the two antibodies measured on nontransfected cells. The amount of CCR5 receptors present at the cell surface was deduced from the quantification of phycoerythrin intensities.
